NCT06811870RecruitingPhase 1
A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients
Guangdong Provincial People's Hospital2 sites in 1 country161 target enrollmentStarted: February 1, 2025Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 161
- Locations
- 2
- Primary Endpoint
- pCR rate after hyperbaric oxygen combined with neoadjuvant therapy in breast cancer patients
Study Overview
Brief Summary
The goal of the study is to explore the efficacy and safety of hyperbaric oxygen in the neoadjuvant treatment of breast cancer patients
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Understand the study process, participate in the study voluntarily, and sign the informed consent form.
- •patients with histopathologically confirmed initial unilateral primary invasive breast cancer, occult breast cancer, Patients with histopathologically confirmed initial unilateral primary invasive breast cancer, with the exception of occult breast cancer, inflammatory breast cancer and eczema-like carcinoma
- •aged ≥ 18 years and ≤ 60 years, female
- •patients who meet the inclusion criteria for neoadjuvant therapy to receive neoadjuvant therapy for breast cancer (locally advanced) Patients with locally advanced breast cancer (AJCC stage III, except T3N1M0) or operable breast cancer, but without breast-conserving or axillary preservation (stage IIA-IIB and T3N1M0) or HER2 positive or TNBC with certain tumour load, or patients with clinical lymph node positivity or tumour size of 2cm and above.)
- •ECOG performance status 0-
- •Adequate bone marrow functional reserve: white blood cell count ≥3.0 x 109/L, neutrophil count ≥1.5 x 109/L; and 1.5 x 109/L; platelet count ≥ 100 x 109/L; haemoglobin ≥ 90 g/L;
- •AST, ALT ≤ 2.5 times the upper limit of normal value, alkaline phosphatase ≤ 2.5 times the upper limit of normal value.
- •Total bilirubin ≤ 1.5 times the upper limit of normal value; serum creatinine ≤ 1.5 times the upper limit of normal value.
- •For non-menopausal or non-surgically sterilised female patients: during treatment and at least 7 months after the last dose of study treatment.
- •For non-menopausal or non-surgically sterilised female patients: consent to contraception during treatment and for at least 7 months after the last dose of study treatment.
Exclusion Criteria
- •Contraindication to hyperbaric oxygen therapy: untreated pneumothorax. Concurrent use of disulfiram. concomitant administration of anti-tumour drugs such as bleomycin, cisplatin, adriamycin concomitant administration of antineoplastic drugs such as bleomycin, cisplatin, adriamycin. Premature and/or low body mass neonates. Lung disease (severe chronic obstructive pulmonary disease).
- •Diseases of the lungs (severe chronic obstructive airway disease, herpetic lung disease, acute or chronic lung infections, uncontrolled asthma, uncontrolled diarrhoea).
- •controlled asthma, untreated pneumothorax), history of previous middle ear surgery, middle ear disease (eustachian tube Dysfunction of the eustachian tube, recurrent episodes of vertigo), ocular disease (retinal detachment).
- •previous hyperbaric oxygen therapy.
- •distant metastases, including lymph node metastases to the contralateral breast and mediastinum.
- •other malignant tumours within the last two years, except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix.
- •pregnancy or lactation
- •uncontrolled hypertension, cardiac, hepatic, renal related disease or other medical or psychiatric conditions.
- •major surgical procedure unrelated to breast cancer within 4 weeks prior to randomisation, or the patient has not fully recovered from such procedure; or has not fully recovered from such surgical intervention.
- •serious or uncontrolled infections that may interfere with study treatment or assessment of study results, including but not limited to Serious or uncontrolled infections that may interfere with study treatment or the evaluation of study results, including but not limited to active hepatitis virus infection, human immunodeficiency virus (HIV) antibody positivity, and pulmonary infections.
- •recent history of thromboembolism and taking full dose anticoagulant medication.
- •any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the study
Arms & Interventions
Hyperbaric Oxygen group
Experimental
Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 times hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).
Intervention: hyperbaric oxygen treatment (Device)
Outcomes
Primary Outcomes
pCR rate after hyperbaric oxygen combined with neoadjuvant therapy in breast cancer patients
Time Frame: After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year)
pCR rate after hyperbaric oxygen combined with neoadjuvant therapy in breast cancer patients
Secondary Outcomes
- life quality(At the time of patient enrolment, Each cycle of chemotherapy (8cycle, each cycle is 3 weeks), Day before surgery, 3 months after surgery.)
- The Miller and payne classification(After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year))
- RCB 0/1 rate(After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year))
- RECIST criteria(After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year))
- Side effects of hyperbaric oxygen therapy(during the hyperbaric oxygen therapy (up to half a year))
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0(through study completion ( an average of half a year))
- the Tumor immune microenvironment of the Hyperbaric Oxygen Therapy and neoadjuvant therapy(the time when the patient enrollment, at the end of the first cycle of neoadjuvant therapy (at about the first month), surgery)
Investigators
Kun Wang
Professor
Guangdong Provincial People's Hospital
Study Sites (2)
Loading locations...
Similar Trials
Unknown
Phase 2
IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal CancerRectal CancerNCT01237665Ottawa Hospital Research Institute15
Recruiting
Phase 2
Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLCNon Small Cell Lung CancerNCT04875585Medical University Innsbruck33
Not yet recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011Advanced Breast CancerNCT06354114CSPC Ouyi Pharmaceutical Co., Ltd.80
Unknown
Phase 2
Endostar + GT in Pulmonary Metastases of Soft Tissue SarcomaSoft Tissue SarcomaNCT01812018Peng Yuan30
Withdrawn
Phase 2
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast CancerBreast CancerNCT02215876Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins